




P3.297: Adebrelimab Combined with Chemotherapy plus Individualized Radiotherapy for LS-SCLC

Guohao Xia¹, Xiangzhi Zhu¹, Yizhi Ge¹
¹Jiangsu Cancer Hospital, Nanjing/CN
Correspondence: 13913976000@163.com



IASLC 2026 World
Conference on Lung Cancer
SEPTEMBER 12 - 15, 2026
SEOUL, REPUBLIC OF KOREA

INTRODUCTION

- The ADRIATIC study has established the standard treatment for limited-stage small cell lung cancer (LS-SCLC).
- The dose fractionation pattern of radiotherapy and the sequence of its combination with immunotherapy still need to be explored.
- This study will investigate the efficacy and safety of adebrelimab (PD-L1 inhibitor) combined with cisplatin/carboplatin and etoposide (EP/EC) plus individualized radiotherapy in the treatment of LS-SCLC.

METHODS

Design:

- This is an open-label, prospective study at Jiangsu Cancer Hospital.
- Key inclusion criteria: ≥18 years, unresectable LS-SCLC, no prior systemic therapy, ECOG 0~1, measurable disease (RECIST v1.1).
- Patients received 2 cycles of adebrelimab + EP/EC. Non-progressive patients were assigned to hypofractionated group (Hypo, 40~60 Gy/10~15 fractions) or hyperfractionated group (Hyper, 45 Gy/30 f, 3 weeks) based on the pre-defined individualized radiotherapy standards, followed by 2~4 more cycles of adebrelimab + EP/EC, then adebrelimab maintenance for up to one year.
- Primary endpoint is the 2-year overall survival (OS) rate.
- To calculate the sample size, the 2-year OS rate of 70% was anticipated in the new group when the 2-year OS rate of the historic control group is 50%.

DISCUSSION AND CONCLUSION

Actionable Take Away Message

- Adebrelimab combined with chemotherapy plus individualized radiotherapy in the treatment of LS-SCLC demonstrated acceptable toxicity, though its efficacy requires further determination due to the short follow-up period.

Future Direction for Research

- How does this study advance the field, benefitting clinicians and patients? Illuminate the way forward, shaping the future of medical research for impactful outcomes.

References:

- Y. Cheng, D. R. Spigel, B. C. Cho, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer, *N Engl J Med.* 2024; 391 (14) 1313-1327.
- CHENG Y, WANG H, MIN X, et al. Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial. *ESMO Open*, 2024, 9(Suppl 3):102771.
- WANG J, ZHOU C, YAO W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment forextensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2022, 23 (6): 739-747.

Artificial Intelligence (AI) Use Disclaimer


DeepSeek was utilized as a language polishing tool for the English writing throughout the preparation of this abstract.

Registration Number: ChiCTR2300077007

Support: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

RESULTS

- From Sep 14, 2023 to Aug 13, 2025, 32 patients with LS-SCLC were enrolled.
- At cutoff (Mar 09, 2026), median follow-up was 19.6 months (95% CI 15.6-23.6).
- 2-year OS rate was 54.0% (95% CI: 31.9-76.2%). For those received Hypo or Hyper treatment, the 2-year OS rate were 52.2% (95% CI: 20.3 84.1%) and 55.4% (95% CI: 25.0-85.8%) respectively.
- The median OS was 24.1 months (95% CI: 14.0-34.1), the median progression-free survival (PFS) was 11.9 months (95% CI: 8.6-15.3) in all patients.
- There were no treatment-related deaths. Treatment-related adverse events (TRAEs) occurred in 31 (97%) patients.



Adverse events	Hypo (n=13)		Hyper (n=19)		ITT (n=32)	
	Grade 1~2	≥Grade 3	Grade 1~2	≥Grade 3	Grade 1~2	≥Grade 3
Any TRAE	8(62%)	5(38%)	12(63%)	6(32%)	20(63%)	11(34%)
Hematological toxicities						
Lymphocyte count decreased	10(77%)	2(15%)	11(58%)	6(32%)	21(66%)	8(25%)
Anemia	5(38%)	0(0)	11(58%)	0(0)	16(50%)	0(0)
Neutrophil count decreased	5(38%)	0(0)	6(32%)	0(0)	11(34%)	0(0)
Platelet count decreased	5(38%)	0(0)	6(32%)	0(0)	11(34%)	0(0)
White blood cell count decreased	6(46%)	0(0)	5(26%)	0(0)	11(34%)	0(0)
Non-hematological toxicities						
GGT increased	6(46%)	1(8%)	7(37%)	0(0)	13(41%)	1(3%)
Hypoalbuminemia	5(38%)	0(0)	8(42%)	0(0)	13(41%)	0(0)
Nausea	4(31%)	0(0)	6(32%)	0(0)	10(31%)	0(0)
Anorexia	3(23%)	0(0)	7(37%)	0(0)	10(31%)	0(0)
Hyponatraemia	3(23%)	0(0)	3(16%)	0(0)	6(19%)	0(0)
Fever	3(23%)	0(0)	3(16%)	0(0)	6(19%)	0(0)
Cough	2(15%)	0(0)	3(16%)	0(0)	5(16%)	0(0)
Pneumonitis	1(8%)	3(23%)	0(0)	0(0)	1(3%)	3(9%)
Pain	3(23%)	0(0)	0(0)	1(5%)	4(13%)	0(0)
Asthenia	2(15%)	0(0)	1(5%)	0(0)	3(9%)	0(0)
Hypokalaemia	1(8%)	0(0)	1(5%)	0(0)	2(6%)	0(0)
Alanine aminotransferase increased	1(8%)	0(0)	0(0)	0(0)	1(3%)	0(0)
Aspartate aminotransferase increased	1(8%)	0(0)	0(0)	0(0)	1(3%)	0(0)
Proteinuria	0(0)	0(0)	1(5%)	0(0)	1(3%)	0(0)
Hypothyroidism	0(0)	0(0)	1(5%)	0(0)	1(3%)	0(0)

	Hypo (n=13)	Hyper (n=19)	ITT (n=32)
Age, years(rang)	60(50-72)	58(45-66)	58(45-75)
Sex			
Male	13(100%)	16(94%)	29(91%)
Female	0	3(16%)	3(9%)
ECOG			
0	1(8%)	0	1(3%)
1	12(92%)	19(100%)	31(97%)
Disease stage T			
1	3(23%)	2(11%)	5(16%)
2	4(31%)	8(42%)	12(38%)
3~4	6(46%)	9(47%)	15(47%)
Disease stage N			
0	2(15%)	2(11%)	4(13%)
2	10(77%)	13(68%)	23(72%)
3	1(8%)	4(21%)	5(16%)
Smoking history			
Never	3(23%)	4(21%)	7(22%)
Former	10(77%)	15(79%)	25(78%)

